Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
4
×
life sciences
national blog main
boston blog main
boston top stories
drugs
boston
fda
national top stories
new york blog main
onpattro
patisiran
san diego blog main
san francisco blog main
acute hepatic porphyrias
akcea therapeutics
akin akinc
alnylam pharmaceuticals
aminolevulinic acid
anylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech
bluebird bio
cannabidiol
cardiomyopathy
dravet syndrome
duchenne muscular dystrophy
dyne therapeutics
epidiolex
facioscapulohumeral muscular dystrophy
fen-phen
fenfluramine
gene therapy
givosiran
gw pharmaceuticals
inotersen
joshua brumm
What
ago
4
×
drug
4
×
fda
rare
alnylam
approved
battle
data
genetic
medicine
medicines
pharmaceuticals
sets
weeks
akcea
amyloidosis
approval
attr
available
biotechs
cannabis
considering
debilitating
derivative
disease
diseases
dyne
early
epilepsy
expected
experimental
eyes
form
gw
gw’s
having
humans
indicated
interference
ipo
Language
unset
Current search:
drug
×
" clinical trials "
×
ago
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug